Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Wong R, et al. Among authors: ippoliti c. Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14. doi: 10.1016/j.bbmt.2004.10.008. Biol Blood Marrow Transplant. 2005. PMID: 15682071 Free article.
Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Gajewski JL, et al. Among authors: ippoliti c. Biol Blood Marrow Transplant. 2002;8(10):550-6. doi: 10.1053/bbmt.2002.v8.pm12434950. Biol Blood Marrow Transplant. 2002. PMID: 12434950 Free article. Clinical Trial.
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.
Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Wong R, et al. Among authors: ippoliti c. Blood. 2003 Oct 15;102(8):3052-9. doi: 10.1182/blood-2003-03-0855. Epub 2003 Jul 3. Blood. 2003. PMID: 12842990 Free article.
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Couriel DR, et al. Among authors: ippoliti c. Biol Blood Marrow Transplant. 2004 Mar;10(3):178-85. doi: 10.1016/j.bbmt.2003.10.006. Biol Blood Marrow Transplant. 2004. PMID: 14993883 Free article.
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.
Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Couriel D, et al. Among authors: ippoliti c. Blood. 2004 Aug 1;104(3):649-54. doi: 10.1182/blood-2003-12-4241. Epub 2004 Apr 6. Blood. 2004. PMID: 15069017 Free article.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. de Lima M, et al. Among authors: ippoliti c. Blood. 2004 Aug 1;104(3):865-72. doi: 10.1182/blood-2003-11-3750. Epub 2004 Apr 15. Blood. 2004. PMID: 15090449 Free article.
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.
Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. Couriel DR, et al. Among authors: ippoliti c. Biol Blood Marrow Transplant. 2009 Dec;15(12):1555-62. doi: 10.1016/j.bbmt.2009.08.003. Epub 2009 Sep 25. Biol Blood Marrow Transplant. 2009. PMID: 19896079 Free PMC article. Clinical Trial.
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.
Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W. Przepiorka D, et al. Among authors: ippoliti c. Blood. 1996 Dec 1;88(11):4383-9. Blood. 1996. PMID: 8943876 Free article. Clinical Trial.
124 results